Steven Cohen’s LLY Holdings & Trades

First Buy
Q4 2014
Duration Held
44 Quarters
Largest Add
Q3 2015
+1.47 M Shares
Current Position
7,119 Shares
$5.43 M Value

Steven Cohen's LLY Position Overview

Steven Cohen (via Point72 Asset Management, L.P.) currently holds 7,119 shares of Eli Lilly and Company (LLY) worth $5.43 M, representing 0.01% of the portfolio. First purchased in 2014-Q4, this long-term strategic position has been held for 44 quarters.

Based on 13F filings since 2013, Steven Cohen has maintained a long-term strategic position in LLY, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2015, adding 1.39 M shares. Largest reduction occurred in Q3 2016, reducing 1.04 M shares.

Analysis based on 13F filings available since 2013 Q2

Steven Cohen's Eli Lilly and Company (LLY) Holding Value Over Time

Track share changes against reported price movement

Quarterly Eli Lilly and Company (LLY) Trades by Steven Cohen

Period Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2014 +76,000 New Buy 76,000 $68.99
Q1 2015 -76,000 Sold Out 76,000 $0.00
Q3 2015 +1.47 M New Buy 1.47 M $83.69
Q4 2015 -695,100 Reduce 47.31% 774,200 $84.26
Q1 2016 +455,404 Add 58.82% 1.23 M $72.01
Q2 2016 +120,676 Add 9.81% 1.35 M $78.75
Q3 2016 -1.04 M Reduce 77.16% 308,400 $80.26
Q4 2016 -301,500 Reduce 97.76% 6,900 $73.48
Q1 2017 +895,700 Add 12981.16% 902,600 $84.11
Q2 2017 +375,549 Add 41.61% 1.28 M $82.30
Q3 2017 -678,149 Reduce 53.06% 600,000 $85.54
Q4 2017 +46,800 Add 7.80% 646,800 $84.46
Q1 2018 +251,891 Add 38.94% 898,691 $77.37
Q2 2018 -152,891 Reduce 17.01% 745,800 $85.33
Q3 2018 -695,800 Reduce 93.30% 50,000 $107.32
Q4 2018 +268,673 Add 537.35% 318,673 $115.72
Q1 2019 -318,673 Sold Out 318,673 $0.00
Q3 2019 +906,761 New Buy 906,761 $111.83
Q4 2019 -325,828 Reduce 35.93% 580,933 $131.43
Q1 2020 -580,933 Sold Out 580,933 $0.00
Q3 2020 +1.32 M New Buy 1.32 M $148.02
Q4 2020 -479,441 Reduce 36.42% 837,100 $168.84
Q1 2021 -837,100 Sold Out 837,100 $0.00
Q3 2021 +87,100 New Buy 87,100 $231.04
Q4 2021 +193,200 Add 221.81% 280,300 $276.22
Q1 2022 -280,300 Sold Out 280,300 $0.00
Q2 2022 +295,800 New Buy 295,800 $324.23
Q3 2022 -6,645 Reduce 2.25% 289,155 $323.35
Q4 2022 -289,155 Sold Out 289,155 $0.00
Q1 2023 +4,425 New Buy 4,425 $343.42
Q2 2023 +87,497 Add 1977.33% 91,922 $468.98
Q3 2023 +90,706 Add 98.68% 182,628 $537.13
Q4 2023 -11,417 Reduce 6.25% 171,211 $582.92
Q1 2024 -45,301 Reduce 26.46% 125,910 $777.96
Q2 2024 -125,910 Sold Out 125,910 $0.00
Q3 2024 +13,158 New Buy 13,158 $885.94
Q4 2024 -13,158 Sold Out 13,158 $0.00
Q1 2025 +54,774 New Buy 54,774 $825.91
Q2 2025 +133,736 Add 244.16% 188,510 $779.53
Q3 2025 -181,391 Reduce 96.22% 7,119 $762.96

Steven Cohen's Eli Lilly and Company Investment FAQs

Steven Cohen first purchased Eli Lilly and Company (LLY) in Q4 2014, acquiring 76,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Steven Cohen has held Eli Lilly and Company (LLY) for 44 quarters since Q4 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Steven Cohen's largest addition to Eli Lilly and Company (LLY) was in Q3 2015, adding 1,469,300 shares worth $122.97 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

According to the latest 13F filing for Q3 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 7,119 shares of Eli Lilly and Company (LLY), valued at approximately $5.43 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

As of the Q3 2025 filing, Eli Lilly and Company (LLY) represents approximately 0.01% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Steven Cohen's peak holding in Eli Lilly and Company (LLY) was 1,469,300 shares, as reported at the end of Q3 2015. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.